NASDAQ: THRDThird Harmonic Bio Inc Stock
$5.79-0.05 (-0.86%)
Updated Jan 23, 2025
THRD Price
$5.79
Fair Value Price
$6.69
Market Cap
$260.89M
52 Week Low
$5.60
52 Week High
$16.94
P/E
-6.03x
P/B
0.88x
P/S
N/A
PEG
N/A
Dividend Yield
N/A
Revenue
$0.00
Earnings
-$39.20M
Gross Margin
N/A
Operating Margin
N/A
Profit Margin
N/A
Debt to Equity
0.03
Operating Cash Flow
-$29M
Beta
0.98
Next Earnings
N/A
Ex-Dividend
N/A
Next Dividend
N/A
THRD Overview
Third Harmonic Bio, Inc., a clinical-stage biopharmaceutical company, focuses on the development of the medicine for the treatment of allergic and inflammatory diseases. It develops THB001, an oral small-molecule KIT inhibitor for the treatment of chronic urticaria, a dermatologic disease driven by mast cell activation that results in red, itchy, painful welts, or hives, as well as for airway and gastrointestinal tract indications. The company was formerly known as Project IGE, Inc. and changed its name to Third Harmonic Bio, Inc. in June 2019. Third Harmonic Bio, Inc. was founded in 2019 and is headquartered in Cambridge, Massachusetts.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine THRD's potential to beat the market
DSell
- Stocks with a Zen Rating of Sell (D) had an average loss of -4.50% per year. Learn More
Zen Rating Component Grades
C
Value
C
Growth
C
Momentum
D
Sentiment
C
Safety
C
Financials
C
Artificial Intelligence
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: Biotech
Industry Rating
F
THRD
Ranked#449 of 556
Ranked#449 of 556
Top Ranked Stocks in Industry
| Name / Ticker | Price | Zen Rating |
|---|---|---|
| $22.14 | A | |
| $122.48 | A | |
| $5.98 | A |
Be the first to know about important THRD news, forecast changes, insider trades & much more!
THRD News
Overview
Due Diligence Score
–
Industry Average (23)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how THRD scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
THRD ($5.79) is undervalued by 13.42% relative to our estimate of its Fair Value price of $6.69 based on Discounted Cash Flow (DCF) modelling, but does not have a significant margin of safety
Below Fair Value Valuation
THRD ($5.79) is not significantly undervalued (13.42%) relative to our estimate of its Fair Value price of $6.69 based on Discounted Cash Flow (DCF) modelling, when including a healthy margin of safety
Significantly Below Fair Value Valuation
THRD is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more THRD due diligence checks available for Premium users.
Valuation
THRD fair value
Fair Value of THRD stock based on Discounted Cash Flow (DCF)
Price
$5.79
Fair Value
$6.69
Undervalued by
13.42%
THRD ($5.79) is undervalued by... subscribe to Premium to read more.
Below Fair Value Valuation
THRD ($5.79) is not significantly... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
THRD is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
THRD price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-6.03x
Industry
-205.94x
Market
30.03x
THRD price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
0.88x
Industry
4.95x
THRD is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
THRD's financial health
Profit margin
Revenue
$0.0
Net Income
-$13.8M
Profit Margin
0%
THRD's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
Assets to liabilities
Assets
$304.5M
Liabilities
$9.6M
Debt to equity
0.03
THRD's short-term assets ($300.23M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
THRD's short-term assets ($300.23M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
THRD's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$8.2M
Investing
$0.0
Financing
$48.9M
THRD's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
THRD vs Biotech Stocks
Third Harmonic Bio Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.